Advaxis to license its ADXS-HPV product candidate to FusionVax – News-Medical.net

Advaxis to license its ADXS-HPV product candidate to FusionVax
News-Medical.net
FusionVax is a private Taiwan-based biopharmaceutical company developing immunotherapies for the treatment of HPV-associated cancers. It is committed to in-licensing and developing early to late phase product candidates with primary disease targets of
Advaxis Announces First Patient Dosed in Brown University Sponsored Anal Business Wire (press release)

all 3 news articles »

View full post on hpv – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *